Trends in Viral Vector-Based Vaccines for Tuberculosis: A Patent Review (2010-2023)

Overview

Journal Vaccines (Basel)

Date 2024 Aug 29

PMID 39204002

Authors

Lana C Santos

Antonio Marcio Santana Fernandes

Izabel Almeida Alves

Mairim Russo Serafini

Leandra da Silva E Silva

Humberto Fonseca de Freitas

Luciana C C Leite

Carina C Santos

Affiliations

Soon will be listed here.

Abstract

Tuberculosis (TB) is an ancient global public health problem. Several strategies have been applied to develop new and more effective vaccines against TB, from attenuated or inactivated mycobacteria to recombinant subunit or genetic vaccines, including viral vectors. This review aimed to evaluate patents filed between 2010 and 2023 for TB vaccine candidates. It focuses on viral vector-based strategies. A search was carried out in Espacenet, using the descriptors "mycobacterium and tuberculosis" and the classification A61K39. Of the 411 patents preliminarily identified, the majority were related to subunit vaccines, with 10 patents based on viral vector platforms selected in this study. Most of the identified patents belong to the United States or China, with a concentration of patent filings between 2013 and 2023. Adenoviruses were the most explored viral vectors, and the most common immunodominant (Mtb) antigens were present in all the selected patents. The majority of patents were tested in mouse models by intranasal or subcutaneous route of immunization. In the coming years, an increased use of this platform for prophylactic and/or therapeutic approaches for TB and other diseases is expected. Along with this, expanding knowledge about the safety of this technology is essential to advance its use.

References

Nascimento I, Rodriguez D, Santos C, Amaral E, Rofatto H, Junqueira-Kipnis A . Recombinant BCG Expressing LTAK63 Adjuvant induces Superior Protection against Mycobacterium tuberculosis. Sci Rep. 2017; 7(1):2109. PMC: 5437048. DOI: 10.1038/s41598-017-02003-9. View

Davison A, Benko M, Harrach B . Genetic content and evolution of adenoviruses. J Gen Virol. 2003; 84(Pt 11):2895-2908. DOI: 10.1099/vir.0.19497-0. View

Groschel M, Sayes F, Simeone R, Majlessi L, Brosch R . ESX secretion systems: mycobacterial evolution to counter host immunity. Nat Rev Microbiol. 2016; 14(11):677-691. DOI: 10.1038/nrmicro.2016.131. View

Cobelens F, Suri R, Helinski M, Makanga M, Weinberg A, Schaffmeister B . Accelerating research and development of new vaccines against tuberculosis: a global roadmap. Lancet Infect Dis. 2022; 22(4):e108-e120. PMC: 8884775. DOI: 10.1016/S1473-3099(21)00810-0. View

Shurygina A, Zabolotnykh N, Vinogradova T, Khairullin B, Kassenov M, Nurpeisova A . Preclinical Evaluation of TB/FLU-04L-An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis. Int J Mol Sci. 2023; 24(8). PMC: 10138401. DOI: 10.3390/ijms24087439. View

Tameris M, Hatherill M, Landry B, Scriba T, Snowden M, Lockhart S . Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet. 2013; 381(9871):1021-8. PMC: 5424647. DOI: 10.1016/S0140-6736(13)60177-4. View

Knight G, Griffiths U, Sumner T, Laurence Y, Gheorghe A, Vassall A . Impact and cost-effectiveness of new tuberculosis vaccines in low- and middle-income countries. Proc Natl Acad Sci U S A. 2014; 111(43):15520-5. PMC: 4217399. DOI: 10.1073/pnas.1404386111. View

Ferko B, Stasakova J, Sereinig S, Romanova J, Katinger D, Niebler B . Hyperattenuated recombinant influenza A virus nonstructural-protein-encoding vectors induce human immunodeficiency virus type 1 Nef-specific systemic and mucosal immune responses in mice. J Virol. 2001; 75(19):8899-908. PMC: 114458. DOI: 10.1128/JVI.75.19.8899-8908.2001. View

Falzon D, Schunemann H, Harausz E, Gonzalez-Angulo L, Lienhardt C, Jaramillo E . World Health Organization treatment guidelines for drug-resistant tuberculosis, 2016 update. Eur Respir J. 2017; 49(3). PMC: 5399349. DOI: 10.1183/13993003.02308-2016. View

10.

Palese P . RNA virus vectors: where are we and where do we need to go?. Proc Natl Acad Sci U S A. 1998; 95(22):12750-2. PMC: 33911. DOI: 10.1073/pnas.95.22.12750. View

11.

Andersen P, Kaufmann S . Novel vaccination strategies against tuberculosis. Cold Spring Harb Perspect Med. 2014; 4(6). PMC: 4031959. DOI: 10.1101/cshperspect.a018523. View

12.

Fuchs J, Bart P, Frahm N, Morgan C, B Gilbert P, Kochar N . Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals. J AIDS Clin Res. 2015; 6(5). PMC: 4648371. DOI: 10.4172/2155-6113.1000461. View

13.

Rowland R, McShane H . Tuberculosis vaccines in clinical trials. Expert Rev Vaccines. 2011; 10(5):645-58. PMC: 3409871. DOI: 10.1586/erv.11.28. View

14.

Wang S, Liang B, Wang W, Li L, Feng N, Zhao Y . Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases. Signal Transduct Target Ther. 2023; 8(1):149. PMC: 10081433. DOI: 10.1038/s41392-023-01408-5. View

15.

Homann D, Teyton L, Oldstone M . Differential regulation of antiviral T-cell immunity results in stable CD8+ but declining CD4+ T-cell memory. Nat Med. 2001; 7(8):913-9. DOI: 10.1038/90950. View

16.

Aronson N, Santosham M, Comstock G, Howard R, Moulton L, Rhoades E . Long-term efficacy of BCG vaccine in American Indians and Alaska Natives: A 60-year follow-up study. JAMA. 2004; 291(17):2086-91. DOI: 10.1001/jama.291.17.2086. View

17.

Sheppard M . Viral vectors for veterinary vaccines. Adv Vet Med. 1999; 41:145-61. PMC: 7149319. DOI: 10.1016/s0065-3519(99)80014-7. View

18.

Russell D . Mycobacterium tuberculosis: here today, and here tomorrow. Nat Rev Mol Cell Biol. 2001; 2(8):569-77. DOI: 10.1038/35085034. View

19.

Uddback I, Cartwright E, Scholler A, Wein A, Hayward S, Lobby J . Long-term maintenance of lung resident memory T cells is mediated by persistent antigen. Mucosal Immunol. 2020; 14(1):92-99. PMC: 7726002. DOI: 10.1038/s41385-020-0309-3. View

20.

Hansen S, Vieville C, Whizin N, Coyne-Johnson L, Siess D, Drummond D . Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15(3):293-9. PMC: 2720091. DOI: 10.1038/nm.1935. View